CAPR is a catalyst-heavy dislocation, not a clean balance-sheet value stock. The November 22, 2026 PDUFA date creates large upside if deramiocel is approved for upper-limb function in Duchenne muscular dystrophy, but the 3-9 advisory committee vote, active class action, heavy short interest and fast cash burn keep the base case deliberately below bullish sell-side targets.
rNPV uses a 35% U.S. probability of success after the adverse cardiomyopathy AdCom but accepted major amendment for upper-limb data. The latest broad analyst consensus ranges around $27-$30 average, with Cantor at $28 on 2026-08-14 and Oppenheimer previously re-opening at $54 after the PDUFA extension; our $15.25 base is materially below that because it haircuts regulatory, litigation and dilution risk. Main sensitivity: each 10 pp change in approval POS moves FV by about $3.25 per share. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Deramiocel U.S. rNPV | 35% POS x $550M peak U.S. sales x 45% EBIT margin / 17% biotech discount rate / 58.1M shares | +10.75 |
| Ex-U.S. option value | 20% POS x $300M peak sales x 35% EBIT margin / 18% discount rate / 58.1M shares | +2.65 |
| Priority Review Voucher option | 35% approval POS x $100M estimated PRV sale value / 58.1M shares | +0.60 |
| Cash runway floor | $237.9M cash and securities minus $80M two-quarter burn / 58.1M shares | +2.72 |
| Litigation / dilution reserve | -15% haircut for class action, NS Pharma arbitration and potential launch financing | -1.47 |
| FV base case | 10.75 + 2.65 + 0.60 + 2.72 - 1.47 | $15.25 |
Short interest is high enough to amplify both directions: approval could force cover, while a CRL validates the crowded bear case.
| Item | FY2023 | FY2024 | FY2025 | 2026E run-rate | Guidance 2026 |
|---|---|---|---|---|---|
| Revenue | $0M | $0M | $0M | $0M | No product revenue before approval |
| Operating expense | N/D | N/D | ~$120M+ | ~$159M | Commercial readiness paced to FDA clarity |
| Net loss | N/D | N/D | N/D | ~$149M | H1 2026 loss $74.7M |
| Cash & securities | N/D | N/D | $318.1M | $237.9M at Q2 | At least 12 months runway |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating expense ($M) | 27.7 | N/D | N/D | 36.8 | 42.9 |
| Net loss ($M) | -25.9 | N/D | N/D | -33.9 | -40.7 |
| End-of-period cash ($M) | N/D | N/D | 318.1 | 278.6 | 237.9 |
Business model - one-asset regulatory bridge
Deramiocel U.S. $0 now; $200-550M peak sales scenario ramping if approved BLA under FDA review, now focused on upper-limb function. Main value driver and main binary risk. PRV / non-dilutive capital $0 now; ~$100M sale option if approved conditional Rare Pediatric Disease PRV could offset launch or trial capital needs, but exists only if approval is granted. StealthX / exosomes $0; programs largely paused on hold Platform optionality is real but strategically subordinated until deramiocel regulatory clarity. Ex-U.S. expansion Europe/Japan engagement; no approved revenue early Could add long-tail value after U.S. clarity; timing and partner economics remain uncertain.
Legal, regulatory and risk analysis
SWOT analysis
- +Cash and securities provide more than one year of runway.
- +HOPE-3 upper-limb endpoint reported statistically significant.
- +Manufacturing facility is operational for initial launch readiness.
- −No product revenue and rising quarterly burn.
- −Single-asset dependency dominates valuation.
- −Recent insider selling weakens governance signal.
- →November PDUFA can unlock approval, PRV sale and launch path.
- →Short interest could create forced buying after positive regulatory news.
- →Europe/Japan pathway could extend asset value.
- !CRL would reset the story toward cash burn and more trials.
- !Class action and arbitration can consume capital and attention.
- !Dilution likely if approval is delayed or launch is capital-heavy.
Summary by assessment area
- Approval is the thesis; CRL is the bear case.
- The amended upper-limb path is plausible but not de-risked.
- Base FV is $15.25 against $9.34 close.
- The bull case is much larger than the base case, but probability-weighted.
- Class action and insider selling deserve explicit monitoring.
- No buyback; capital allocation is survival and launch readiness.
Sources: price/market data from ChartExchange and Investing.com historical daily prices; market cap/shares/52W from SEC 10-Q, Schwab/StockAnalysis-style market data and direct price x shares calculation; Q1/Q2 financials from Capricor press releases and SEC 10-Q; regulatory status from Capricor Q2 release, FDA advisory committee sponsor briefing document and August 24 PDUFA-extension release; short interest from MarketBeat and ChartExchange; analyst targets from MarketBeat, StockAnalysis, Benzinga, Yahoo Finance and Investing.com analyst pages; insider trading from MarketBeat; class action from Pomerantz/Bragar/Kessler notices; peer comparables from StockAnalysis/Bloomberg Linea/market-data pages for SRPT, PTCT and EWTX. Market data - last verified close 2026-09-22: CAPR $9.34, market cap ~$543M, 52W range $2.96-$40.37, 58.11M shares outstanding. Short interest: 42.02% float. This document is for informational purposes only and does not constitute financial or investment advice.